Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Peter Michael Ellis, Geoffrey Liu, Michael Millward, Francesco Perrone, Frances A. Shepherd, Sophie Sun, Byoung Chul Cho, Alessandro Morabito, Martin R. Stockier, Rafal Wierzbicki, Victor Cohen, Normand Blais, Randeep S. Sangha, Adolfo G. Favaretto, Jin Hyoung Kang, Carolyn F. Wilson, Joseph O'Connell, Keyue Ding, Glenwood D. Goss, Penelope Ann Bradbury

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2014
Externally publishedYes
Event50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 30 May 20143 Jun 2014

Cite this